Literature DB >> 2932050

Abnormalities of the nucleus basalis in Down's syndrome.

M F Casanova, L C Walker, P J Whitehouse, D L Price.   

Abstract

One of the most striking manifestations of Down's syndrome is profound mental retardation. Furthermore, after 35 years of age, many patients with Down's syndrome develop clinical and pathological features of Alzheimer's disease. Since brains of patients with Alzheimer's disease show significant loss of neurons in the nucleus basalis of Meynert (nbM), we sought to establish normal standards of nbM neurons in persons with Down's syndrome and to determine whether reductions in the number of neurons occur with increasing age. The number and size of neurons in the nbM were measured in selected sagittal sections from 5 patients with Down's syndrome and 5 age-matched controls. The patients (age range, 16 to 56 years) had 29% fewer nbM neurons than controls, and the oldest patient had the lowest cell count of all subjects. The size of nbM neurons did not differ significantly between the two groups. Our results show that the nbM contains fewer neurons in young persons with Down's syndrome than in normal controls and suggest that the number of these nerve cells may be further reduced in older persons with Down's syndrome.

Entities:  

Mesh:

Year:  1985        PMID: 2932050     DOI: 10.1002/ana.410180306

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  39 in total

1.  Nerve growth factor corrects developmental impairments of basal forebrain cholinergic neurons in the trisomy 16 mouse.

Authors:  P Corsi; J T Coyle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

2.  The Link between Alzheimer's Disease and Down Syndrome. A Historical Perspective.

Authors:  Ahmad Salehi; J Wesson Ashford; Elliott J Mufson
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

3.  Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome.

Authors:  Brian E Powers; Ramon Velazquez; Christy M Kelley; Jessica A Ash; Myla S Strawderman; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Brain Struct Funct       Date:  2015-12-30       Impact factor: 3.270

4.  A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model.

Authors:  Jason Lockrow; Heather Boger; Greg Gerhardt; Gary Aston-Jones; David Bachman; Ann-Charlotte Granholm
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice.

Authors:  Christy M Kelley; Brian E Powers; Ramon Velazquez; Jessica A Ash; Stephen D Ginsberg; Barbara J Strupp; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2014-04-15       Impact factor: 3.215

Review 6.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

Review 7.  Down syndrome: the brain in trisomic mode.

Authors:  Mara Dierssen
Journal:  Nat Rev Neurosci       Date:  2012-12       Impact factor: 34.870

8.  The nucleus basalis of Meynert in multi-infarct (vascular) dementia.

Authors:  D M Mann; P O Yates; B Marcyniuk
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

9.  Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice.

Authors:  Jessica A Ash; Ramon Velazquez; Christy M Kelley; Brian E Powers; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Neurobiol Dis       Date:  2014-06-14       Impact factor: 5.996

Review 10.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.